Cargando…

Targeting sickle cell disease root-cause pathophysiology with small molecules

The complex, frequently devastating, multi-organ pathophysiology of sickle cell disease has a single root cause: polymerization of deoxygenated sickle hemoglobin. A logical approach to disease modification is, therefore, to interdict this root cause. Ideally, such interdiction would utilize small mo...

Descripción completa

Detalles Bibliográficos
Autor principal:	Saunthararajah, Yogen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717594/ https://www.ncbi.nlm.nih.gov/pubmed/31399526 http://dx.doi.org/10.3324/haematol.2018.207530

Ejemplares similares

Pathophysiological insights in sickle cell disease
por: Odièvre, Marie-Hélène, et al.
Publicado: (2011)

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells
por: Enane, Francis O., et al.
Publicado: (2018)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation
por: Saunthararajah, Yogen
Publicado: (2020)

Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment
por: Inusa, Baba P. D., et al.
Publicado: (2019)

Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology
por: Lizarralde-Iragorri, Maria A., et al.
Publicado: (2020)

Erythroid Adhesion Molecules in Sickle Cell Anaemia Infants: Insights Into Early Pathophysiology
por: Brousse, Valentine, et al.
Publicado: (2014)

Innate immune cells, major protagonists of sickle cell disease pathophysiology
por: Allali, Slimane, et al.
Publicado: (2020)

Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease
por: Ashouri, Rani, et al.
Publicado: (2021)

Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities
por: Alramadhani, Dina, et al.
Publicado: (2022)

What's New in the Pathophysiology of Sickle Cell Disease?
por: Adekile, Adekunle D.
Publicado: (2013)

Sickling Cells, Cyclic Nucleotides, and Protein Kinases: The Pathophysiology of Urogenital Disorders in Sickle Cell Anemia
por: Claudino, Mário Angelo, et al.
Publicado: (2012)

5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer
por: Daifuku, Richard, et al.
Publicado: (2017)

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions
por: Zavras, Phaedon D., et al.
Publicado: (2021)

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
por: Glaros, Alexander K., et al.
Publicado: (2021)

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway
por: Karan, Dev, et al.
Publicado: (2023)

The Sickled Cell: From Myths to Molecules
por: Chelmow, David
Publicado: (1987)

High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
por: Ebrahem, Quteba, et al.
Publicado: (2012)

Sickle Cell Anemia, the First Molecular Disease: Overview of Molecular Etiology, Pathophysiology, and Therapeutic Approaches
por: Steinberg, Martin H.
Publicado: (2008)

Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction
por: Uchida, Naoya, et al.
Publicado: (2014)

Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas
por: von Knebel Doeberitz, Nikolaus, et al.
Publicado: (2022)

Impact of Abnormal Leukocyte Count in the Pathophysiology of Sickle Cell Anemia
por: Yousif, Tagwa Yousif Elsayed
Publicado: (2022)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Roles of Small-Molecule Compounds in Plant Adventitious Root Development
por: Deng, Yuzheng, et al.
Publicado: (2019)

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion
por: Chilakala, Sujatha, et al.
Publicado: (2019)

Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
por: Velcheti, Vamsidhar, et al.
Publicado: (2015)

Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF
por: Ibanez, Vinzon, et al.
Publicado: (2023)

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study
por: Molokie, Robert, et al.
Publicado: (2017)

Targeting Th17 Cells with Small Molecules and Small Interference RNA
por: Lin, Hui, et al.
Publicado: (2015)

Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease
por: Aprile, Annamaria, et al.
Publicado: (2022)

Rheumatoid Arthritis in Sickle-Cell Population: Pathophysiologic Insights, Clinical Evaluation and Management
por: McFarlane, Isabel M, et al.
Publicado: (2017)

Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease
por: Henry, Eric R., et al.
Publicado: (2020)

Hidden behind thromboinflammation: revealing the roles of von Willebrand factor in sickle cell disease pathophysiology
por: Vital, Eudorah F., et al.
Publicado: (2023)

Small-Molecule Targets in Tumor Immunotherapy
por: Zhu, Hui-Fang, et al.
Publicado: (2018)

Small molecule inhibitors targeting the cancers
por: Liu, Gui‐Hong, et al.
Publicado: (2022)

Small Molecules Targeting Viral RNA
por: Mathez, Gregory, et al.
Publicado: (2023)

Biologic Complexity in Sickle Cell Disease: Implications for Developing Targeted Therapeutics
por: Gee, Beatrice E.
Publicado: (2013)

Polymorphism of the endothelin-1 gene (rs5370) is a potential contributor to sickle cell disease pathophysiology
por: Navarro, Kristen G., et al.
Publicado: (2016)

Adhesion molecules and cerebral microvascular hemodynamic abnormalities in sickle cell disease
por: Abi Rached, Noor Mary, et al.
Publicado: (2022)

Sickle Cell Disease and Pregnancy
por: Jain, Dipty, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4memmpk7k14mm4vevsnsadnug4